Altered Expression and Splicing of ESRP1 in Malignant Melanoma Correlates with Epithelial-Mesenchymal Status and Tumor-Associated Immune Cytolytic Activity.

MLA

Yao, Jun, et al. “Altered Expression and Splicing of ESRP1 in Malignant Melanoma Correlates with Epithelial-Mesenchymal Status and Tumor-Associated Immune Cytolytic Activity.” Cancer Immunology Research, vol. 4, no. 6, June 2016, pp. 552–61. EBSCOhost, https://doi.org/10.1158/2326-6066.CIR-15-0255.

APA

Yao, J., Caballero, O. L., Huang, Y., Lin, C., Rimoldi, D., Behren, A., Cebon, J. S., Hung, M.-C., Weinstein, J. N., Strausberg, R. L., & Zhao, Q. (2016). Altered Expression and Splicing of ESRP1 in Malignant Melanoma Correlates with Epithelial-Mesenchymal Status and Tumor-Associated Immune Cytolytic Activity. Cancer Immunology Research, 4(6), 552–561. https://doi.org/10.1158/2326-6066.CIR-15-0255

Chicago

Yao, Jun, Otavia L Caballero, Ying Huang, Calvin Lin, Donata Rimoldi, Andreas Behren, Jonathan S Cebon, et al. 2016. “Altered Expression and Splicing of ESRP1 in Malignant Melanoma Correlates with Epithelial-Mesenchymal Status and Tumor-Associated Immune Cytolytic Activity.” Cancer Immunology Research 4 (6): 552–61. doi:10.1158/2326-6066.CIR-15-0255.